BCLC™ NAD⁺ Supplement System Targeting SIRT1: A Time-Sequential Biphasic NMN-Resveratrol-Quercetin Formulation with Supporting Clinical and Pharmacological Evidence

Nour-Eddine Ziraoui; Mateo Salazar; Alexander Kensington

doi:10.62051/ijphmr.v6n4.06

Authors

Nour-Eddine Ziraoui
Mateo Salazar
Alexander Kensington

DOI:

https://doi.org/10.62051/ijphmr.v6n4.06

Keywords:

NAD+, NMN, SIRT1, Resveratrol, Quercetin, Piperine, Trimethylglycine, Biphasic release, Cyclodextrin, Formulation science

Abstract

Background: Age-associated decline in NAD+ is closely linked to reduced SIRT1 activity and impaired metabolic resilience. The disclosed BCLC™ system combines NMN, trans-resveratrol, quercetin, piperine, and trimethylglycine within a time-sequential biphasic release architecture. Objective: We retained the disclosed composition, formulation parameters, figures, and performance data, and further matched them with published human and mechanistic evidence relevant to the system modules. Methods: We summarized the disclosed active-component window, release design, and in-vitro endpoints, and compared them with peer-reviewed studies on NMN, resveratrol, quercetin, piperine, methyl-donor metabolism, and cyclodextrin-based solubility engineering. Results: The disclosed system outperformed a conventional comparator in reported cell and dissolution endpoints, including 4.1-5.5-fold SIRT1-pathway activation, 95.6-98.8% nicotinamide clearance, >=36-48 h intracellular NAD+ maintenance, and markedly improved 15-min dissolution of resveratrol, quercetin, and piperine. Published human studies consistently showed that NMN raises blood NAD+ and is generally well tolerated, while resveratrol displayed context-dependent metabolic and SIRT1-related effects and quercetin showed selective cardiometabolic and insulin-sensitivity benefits. Human evidence supporting piperine and methyl-donor support was indirect but mechanistically relevant. Conclusion: We consider the disclosed BCLC™ architecture biologically plausible and better supported than a simple mixed formulation.

References

[1] BCLC™ NMN Composite Anti-Aging Formulation for Activating the SIRT1 Pathway and a Preparation Thereof. Source formulation disclosure/manuscript, 2026.

[2] Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021; 372(6547):1224-1229. doi:10.1126/science.abe9985.

[3] Okabe K, Yaku K, Uchida Y, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022; 9:868640. doi:10.3389/fnut.2022.868640.

[4] Yi L, Maier AB, Tao O, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023; 45(1):29-43. doi:10.1007/s11357-022-00705-1.

[5] Morifuji M, Sato D, Odagiri H, et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. Geroscience. 2024; 46(5):4671-4688. doi:10.1007/s11357-024-01171-0.

[6] Timmers S, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 14(5):612-622. doi:10.1016/j.cmet.2011.10.002.

[7] Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012; 16(5):658-664. doi:10.1016/j.cmet.2012.09.015.

[8] Mansur AP, Roggerio A, Goes MFS, et al. Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial. Int J Cardiol. 2017; 227:788-794. doi:10.1016/j.ijcard.2016.10.058.

[9] Wightman EL, Reay JL, Haskell CF, et al. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br J Nutr. 2014; 112(2):203-213. doi:10.1017/S0007114514000737.

[10] Brüll V, Burak C, Stoffel-Wagner B, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. Br J Nutr. 2015; 114(8):1263-1277. doi:10.1017/S0007114515002950.

[11] Rezvan N, Moini A, Janani L, et al. Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial. Horm Metab Res. 2017; 49(2):115-121. doi:10.1055/s-0042-118705.

[12] Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003; 133(12):4135-4138. doi:10.1093/jn/133.12.4135.

[13] Hong S, Zhai B, Pissios P. Nicotinamide N-Methyltransferase Interacts with Enzymes of the Methionine Cycle and Regulates Methyl Donor Metabolism. Biochemistry. 2018; 57(40):5775-5779. doi:10.1021/acs.biochem.8b00561.

[14] Zheng Y, Chow AHL. Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin/quercetin complex. Drug Dev Ind Pharm. 2009; 35(6):727-734. doi:10.1080/03639040802526805.